CD4 and neoplasm: While targeting glucocorticoid-induced TNFR-related receptor (GITR) in Treg cells promoted CD4+ Tregs differentiation into CD4+ effector T cells, attenuated Treg cell-mediated suppression of anti-tumor immune response, and induced robust anti-tumor effector cells in GBM [63].